# Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

Source: https://onco.cc/trials/nct06234098/  
OnCo record `nct06234098` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AT-1965 Liposome Injection in advanced solid tumours, run by Alyssum Therapeutics, now recruiting.

## Summary

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors is a phase 1/2 interventional study registered as NCT06234098 by Alyssum Therapeutics, with 100 participants planned, started 2024-02-13 and due to reach its primary completion in 2026-12. Interventions recorded: AT-1965 Liposome Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06234098
- Phase: 1/2
- Setting: A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
- Sponsor: Alyssum Therapeutics
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06234098: https://clinicaltrials.gov/study/NCT06234098

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06234098.json